The U.S. Food and Drug Administration has granted Fast Track designation to Idera Pharmaceuticals’ lead development candidate, IMO-2125. The treatment is to be used in combination with Ipilimumab for the treatment of anti-PD-1 refractory metastatic melanoma in combination with ipilimumab therapy. IMO-2125 received orphan drug designation from the FDA in 2017 for the treatment of melanoma Stages IIb to IV. It signals the immune system to create and activate cancer-fighting cells (T-cells) to...